Investigation of the Persistence of SARS-CoV-2 in the Olfactory Mucosa of Patients With Prolonged Symptoms of COVID-19
NCT ID: NCT05220241
Last Updated: 2025-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
51 participants
INTERVENTIONAL
2022-07-01
2025-07-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Cognitive disorders (psychic slowing down, lack of clarity in thought, difficulty in remembering certain facts, difficulty in performing double tasks, difficulty in finding words).
* Sensory disturbances such as burning or tingling with or without root topography, dizziness.
* Neurovegetative manifestations: sudden tachycardia, palpitations, vasomotor disorders, excessive sweating, digestive disorders or post prandial malaise, feelings of malaise (lipothymia with or without hypotension), dyspnea or a feeling of dyspnea, urinary disorders
* Sleep disorders (insomnia, sleep fragmentation, nightmares or hypersomnia)
* Tension type headaches.
The mechanisms explaining the occurrence of these symptoms are still debated. An important result is the recent demonstration by the UK's National Statistics Office that people with "long COVID" may, for some, remain carriers of the SARS-CoV-2 virus for several months. So far, viral persistence has only been demonstrated in a few specific cases of immunocompromised people, almost all of them having been hospitalized.
Recently, in a pilot study conducted jointly by the Institut Pasteur and AP-HP, we demonstrated that viral RNA could be found in immunocompetent patients with prolonged neurological symptoms after COVID-19 (Melo et al 2021). This study concerned 4 patients explored by micro-brushing the mucous membrane of the olfactory cracks under local anesthesia more than 4 months after the initial COVID-19. In all patients, SARS-CoV-2 RNA persisted in significant amounts.
Although this demonstration currently only concerns a small number of people, this study provides evidence that the virus can remain hidden in the olfactory cracks (a tissue that is part of the nervous system), including in people with PCR nasopharyngeal and / or SARS-CoV-2 serology become negative. This persistence of the virus after a so-called "acute" infection is not unique. In EBOLA virus disease, some people have been shown to keep the virus in their semen for several months.
It is now necessary to determine whether this persistence is specific to long COVID, what are the mechanisms and the consequences of this persistence of the virus.
One of the hypotheses is that the virus would persist in endothelial cells and / or support cells. Intermittent reactivation of the virus would lead to intermittent inflammation, secretion of pro-inflammatory cytokines, activation of coagulation and innate immunity cells (monocytes, mast cells, astrocytes, cerebral glial cells) or adaptive This activation could be due to origin of possible micro-thrombosis responsible for a decrease in the oxygen supply in the tissues. This tissue hypoxia could cause the intermittent "brain fog" complained about by patients and the cerebral hypo-metabolisms seen on CT scans. The virus could infect other cells as well, and the issue of direct infection of neurons remains unresolved.
In this study, we want to assess whether viral persistence is specific to patients with prolonged symptoms following COVID-19, to assess whether the presence of SARS-CoV-2 RNA is correlated with the ability of the virus to replicate, study the cellular abnormalities associated with the presence of viruses, and correlate the observed cellular and virological abnormalities with the clinical profile of patients.
We are interested in central neurological disorders, in particular cognitive disorders, because they are often in the foreground, and they are by far the most disabling symptoms for patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Case : patient with 1st episode of COVID-19 and persistence of neurocognitive complaint
Patient with a 1st episode of COVID-19 in the 12 months preceding inclusion and presenting persistence of neurocognitive complaint beyond 4 weeks
Nasopharyngeal swab for RT-PCR SARS-CoV-2
2 nasal swabs (one per nostril) of olfactory mucosa cells under local anesthesia for SARS-CoV-2 RT-PCR and pathological analysis
Control : Patient with a 1st episode of COVID-19 cured and without neurocognitive complaint
Patient with a cured 1st episode of COVID-19 (without persisting symptoms beyond 4 weeks) in the 12 months preceding inclusion and without neurocognitive complaint
Nasopharyngeal swab for RT-PCR SARS-CoV-2
2 nasal swabs (one per nostril) of olfactory mucosa cells under local anesthesia for SARS-CoV-2 RT-PCR and pathological analysis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nasopharyngeal swab for RT-PCR SARS-CoV-2
2 nasal swabs (one per nostril) of olfactory mucosa cells under local anesthesia for SARS-CoV-2 RT-PCR and pathological analysis
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years old and \<60 years old
* Good oral and written command of French
* Level of education ≥ 7 years of schooling
* Initial episode of COVID-19 within 2 to 12 months
* Symptomatic initial episode of COVID-19
* Initial symptoms not explained by another diagnosis
* Initial episode documented by RT-PCR positive for SARS-CoV-2 and / or positive antigen test and / or positive serology (in the absence of vaccination)
* Express consent to participate in the study
* Affiliate or beneficiary of a social security scheme
Case group:
* Presence of at least one of the initial symptoms beyond 4 weeks following the onset of the acute phase of the disease
* Prolonged symptoms not explained by another diagnosis with no known link to COVID-19
* Neurocognitive complaint (s) previously objectified by a neurologist and after completion of a neuro-psychological assessment
* Impact of neurocognitive disorders on daily life authenticated by a Glasgow outcome scale extended ≤ 7 (see appendix 1)
* Evolution of complaints for 2 to 12 months compared to the date of their first appearance
Exclusion Criteria
* Pregnant or breastfeeding woman
* At least one neurological pathology among:
* encephalopathy
* encephalitis
* severe neurological form of the initial episode of COVID-19
* neurodegenerative disease
* History of stroke
* Serious psychiatric history
* Known nasal sinus pathology
* Hemostatic disorder
* Taking aspirin in the 15 days preceding the sample
* Treatment with anticoagulants
* Known allergy to lidocaine
\- Positive SARS-CoV-2 RT-PCR on nasopharyngeal sample on the day of inclusion
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hotel Dieu Hospital
OTHER
Institut Pasteur
INDUSTRY
Hôpital Lariboisière Fernand Widal
OTHER
Fondation Ophtalmologique Adolphe de Rothschild
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mathieu Veyrat, Dr
Role: PRINCIPAL_INVESTIGATOR
Hôpital Fondation A. de Rothschild
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Lariboisière-Fernand-Widal
Paris, , France
Hôpital Fondation A. de Rothschild
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MVT_2021_26
Identifier Type: -
Identifier Source: org_study_id